{"id":"higher-dose-inhaled-corticosteroids","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oropharyngeal candidiasis"},{"rate":"5-10","effect":"Dysphonia / hoarseness"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Inhaled corticosteroids are potent anti-inflammatory agents that work locally in the airways to decrease recruitment and activation of inflammatory cells, reduce mucus production, and restore airway function. By delivering the drug directly to the lungs via inhalation, higher doses can be achieved at the site of disease while minimizing systemic exposure and side effects compared to oral corticosteroids.","oneSentence":"Higher-dose inhaled corticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:59:04.512Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (maintenance and control)"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT06419413","phase":"","title":"A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-01-08","conditions":"Asthma","enrollment":355},{"nctId":"NCT06932263","phase":"PHASE2","title":"Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-26","conditions":"Asthma","enrollment":540},{"nctId":"NCT06948396","phase":"","title":"Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-25","conditions":"Asthma","enrollment":300},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT07328035","phase":"","title":"Remission in Adults With Severe Asthma in Thailand","status":"NOT_YET_RECRUITING","sponsor":"Thammasat University","startDate":"2026-01-01","conditions":"Severe Asthma, Asthma Control Level","enrollment":230},{"nctId":"NCT06029595","phase":"PHASE2","title":"Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-26","conditions":"Uncontrolled Asthma","enrollment":517},{"nctId":"NCT05274815","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-17","conditions":"Asthma","enrollment":305},{"nctId":"NCT06795906","phase":"PHASE1","title":"A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-28","conditions":"Asthma","enrollment":24},{"nctId":"NCT03784781","phase":"","title":"Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-06-09","conditions":"Severe Asthma","enrollment":""},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT05919394","phase":"PHASE4","title":"Triple vs High Dose Inhaled CORticosteroids","status":"WITHDRAWN","sponsor":"Galaxia Empírica","startDate":"2023-06-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT05292586","phase":"PHASE3","title":"A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-08-31","conditions":"Asthma","enrollment":1377},{"nctId":"NCT04643158","phase":"PHASE2","title":"Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT04053634","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-26","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":689},{"nctId":"NCT01718197","phase":"","title":"Severe Asthma Research Program (SARP)- San Francisco Clinical Site","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-11","conditions":"Asthma","enrollment":151},{"nctId":"NCT02103348","phase":"","title":"Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-09","conditions":"Asthma","enrollment":25},{"nctId":"NCT05757583","phase":"","title":"Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-04-05","conditions":"Asthma","enrollment":80},{"nctId":"NCT05819541","phase":"PHASE2","title":"Treating Exacerbations of Asthma With Oral Montelukast in Children","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-20","conditions":"Status Asthmaticus","enrollment":90},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT03692676","phase":"","title":"Characteristics of Pts Initiating Spiriva Respimat in Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-05","conditions":"Asthma","enrollment":116133},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT03564236","phase":"NA","title":"Nasal High-Flow in COPD","status":"RECRUITING","sponsor":"Marieke Duiverman","startDate":"2018-10-01","conditions":"COPD Exacerbation","enrollment":136},{"nctId":"NCT05018598","phase":"PHASE4","title":"Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-25","conditions":"Asthma","enrollment":320},{"nctId":"NCT03788057","phase":"NA","title":"Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma","status":"COMPLETED","sponsor":"National Institute for Tuberculosis and Lung Diseases, Poland","startDate":"2016-02-01","conditions":"Asthma Chronic","enrollment":58},{"nctId":"NCT03299322","phase":"PHASE2","title":"A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2017-10-01","conditions":"Bronchial Asthma","enrollment":240},{"nctId":"NCT03186209","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-07","conditions":"Asthma","enrollment":695},{"nctId":"NCT03479138","phase":"","title":"Non-Eosinophilic Neutrophilic Asthma","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2018-02-21","conditions":"Neutrophilic Asthma","enrollment":10},{"nctId":"NCT05478902","phase":"NA","title":"Effectiveness of Non-surgical Management in Rotator Cuff Calcific Tendinopathy (THE EFFECT TRIAL)","status":"UNKNOWN","sponsor":"University of Valencia","startDate":"2023-05-01","conditions":"Rotator Cuff Tendinosis, Rotator Cuff Injuries, Shoulder Tendinitis","enrollment":116},{"nctId":"NCT05078021","phase":"","title":"Phenotyping Disease Severity in Asthma","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2022-04-21","conditions":"Asthma","enrollment":60},{"nctId":"NCT04742504","phase":"","title":"Interaction Between Benralizumab and Basophils in Eosinophilic Asthma","status":"COMPLETED","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2021-09-07","conditions":"Asthma; Eosinophilic","enrollment":20},{"nctId":"NCT05110976","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-12-16","conditions":"Asthma","enrollment":170},{"nctId":"NCT03557307","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-08-01","conditions":"Asthma","enrollment":598},{"nctId":"NCT03620747","phase":"PHASE3","title":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-30","conditions":"Asthma","enrollment":393},{"nctId":"NCT05689931","phase":"","title":"Blood Leukocyte Profiling in Eosinophilic Type 2 Asthma: Influence of Systemic IL-5 Targeting","status":"UNKNOWN","sponsor":"Region Skane","startDate":"2023-02-01","conditions":"Asthma","enrollment":80},{"nctId":"NCT04193150","phase":"","title":"Uncontrolled and Possible Severe Asthma in Denmark","status":"UNKNOWN","sponsor":"Copenhagen University Hospital, Hvidovre","startDate":"2022-10","conditions":"Asthma","enrollment":550},{"nctId":"NCT01397162","phase":"PHASE2","title":"Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-21","conditions":"Asthma","enrollment":29},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT04206761","phase":"PHASE3","title":"Investigating the Effects of QVM149 on MRI Ventilation Defects","status":"WITHDRAWN","sponsor":"Dr. Grace Parraga","startDate":"2021-12-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT01460862","phase":"","title":"Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Asthma","enrollment":""},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT03345407","phase":"PHASE2","title":"Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":943},{"nctId":"NCT02676089","phase":"PHASE3","title":"TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04-06","conditions":"Asthma","enrollment":1433},{"nctId":"NCT01761630","phase":"","title":"The Severe Asthma Research Program III-Boston Clinical Site","status":"COMPLETED","sponsor":"Elliot Israel, MD","startDate":"2012-12","conditions":"Asthma","enrollment":126},{"nctId":"NCT00214539","phase":"NA","title":"Research in Severe Asthma (RISA) Trial","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2004-04","conditions":"Asthma","enrollment":34},{"nctId":"NCT04416399","phase":"PHASE2","title":"STerOids in COVID-19 Study","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2020-07-16","conditions":"Coronavirus Infection","enrollment":146},{"nctId":"NCT04031261","phase":"","title":"National Validation and Sensitivity to Change of the SAQ","status":"COMPLETED","sponsor":"University Hospital Plymouth NHS Trust","startDate":"2019-04-10","conditions":"Asthma, Severe Asthma","enrollment":410},{"nctId":"NCT01185275","phase":"","title":"A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-08","conditions":"Asthma","enrollment":133},{"nctId":"NCT03964220","phase":"","title":"Impact of Tiotropium Add-on Therapy in Patients With Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-15","conditions":"Asthma","enrollment":7857},{"nctId":"NCT03137043","phase":"","title":"Prevalence of Severe Asthma in Spanish Hospitals","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-11-22","conditions":"Asthma","enrollment":356},{"nctId":"NCT01554488","phase":"PHASE4","title":"Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2013-03-12","conditions":"Asthma, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea","enrollment":25},{"nctId":"NCT00903227","phase":"PHASE4","title":"Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-12","conditions":"Asthma, Allergic Rhinitis","enrollment":25},{"nctId":"NCT02528214","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-15","conditions":"Asthma","enrollment":210},{"nctId":"NCT00159263","phase":"NA","title":"Effect of Symbicort on GR Localisation in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2004-11","conditions":"Asthma","enrollment":10},{"nctId":"NCT04084613","phase":"","title":"Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece","status":"UNKNOWN","sponsor":"Attikon Hospital","startDate":"2017-01","conditions":"Severe Eosinophilic Asthma","enrollment":150},{"nctId":"NCT02902809","phase":"PHASE3","title":"A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2016-11-11","conditions":"Inadequately Controlled Asthma","enrollment":28},{"nctId":"NCT01912872","phase":"PHASE4","title":"Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-11","conditions":"Severe IgE-mediated Asthma","enrollment":112},{"nctId":"NCT02414854","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04-27","conditions":"Asthma","enrollment":1902},{"nctId":"NCT02075255","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-28","conditions":"Asthma","enrollment":220},{"nctId":"NCT00695604","phase":"PHASE2","title":"Repeated High-dose Inhaled Corticosteroids for Asthma","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2008-05","conditions":"Asthma","enrollment":""},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT01544634","phase":"PHASE2","title":"Beta Blocker Therapy in Mild to Moderate Asthmatics","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2012-04-04","conditions":"Asthma","enrollment":16},{"nctId":"NCT01716754","phase":"PHASE2","title":"Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Asthma","enrollment":471},{"nctId":"NCT02336425","phase":"PHASE2","title":"Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09","conditions":"Asthma","enrollment":10},{"nctId":"NCT00327197","phase":"PHASE1","title":"Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2005-08-02","conditions":"Asthma","enrollment":47},{"nctId":"NCT00217854","phase":"NA","title":"Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2001-09","conditions":"Asthma","enrollment":27},{"nctId":"NCT01875003","phase":"PHASE3","title":"A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-31","conditions":"Asthma","enrollment":348},{"nctId":"NCT01928771","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09-19","conditions":"Asthma","enrollment":2681},{"nctId":"NCT01948401","phase":"PHASE2","title":"A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07","conditions":"Asthma","enrollment":54},{"nctId":"NCT01961154","phase":"NA","title":"Stepping Down of Asthma Medication in Controlled Asthma","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Asthma","enrollment":56},{"nctId":"NCT01704495","phase":"PHASE2","title":"A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11","conditions":"Asthma","enrollment":1147},{"nctId":"NCT02671773","phase":"","title":"Characterising the Microbiota in Asthma","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2014-06","conditions":"Asthma","enrollment":72},{"nctId":"NCT00975195","phase":"PHASE4","title":"Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2488},{"nctId":"NCT01976767","phase":"","title":"Longitudinal Assessment of Adults With Severe Asthma","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2011-04","conditions":"Asthma","enrollment":725},{"nctId":"NCT02181335","phase":"PHASE3","title":"Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-10","conditions":"Asthma","enrollment":684},{"nctId":"NCT01431924","phase":"","title":"Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Asthma","enrollment":7779},{"nctId":"NCT00705341","phase":"PHASE4","title":"MethaCholine Bronchoprovocation Study (MeCIS)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2009-01","conditions":"Asthma","enrollment":219},{"nctId":"NCT01334853","phase":"","title":"A Study to Assess Selected Biomarkers in Subjects Requiring Daily Inhaled Corticosteroids for Persistent Asthma","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2011-01","conditions":"Asthma","enrollment":97},{"nctId":"NCT00393367","phase":"PHASE4","title":"Budesonide Inhalation Suspension for Acute Asthma in Children","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2006-12","conditions":"Asthma, Acute Asthma, Reactive Airway Exacerbation","enrollment":179},{"nctId":"NCT00004500","phase":"PHASE3","title":"Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome","status":"TERMINATED","sponsor":"Windtree Therapeutics","startDate":"2000-03","conditions":"Meconium Aspiration","enrollment":69},{"nctId":"NCT00314574","phase":"PHASE3","title":"A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Asthma","enrollment":850},{"nctId":"NCT01200108","phase":"PHASE2","title":"AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma","status":"COMPLETED","sponsor":"Activaero GmbH","startDate":"2010-03","conditions":"Asthma","enrollment":""},{"nctId":"NCT01381367","phase":"PHASE4","title":"PPSV23 Pneumococcal Vaccine in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flovent® is a registered trademark of GlaxoSmithKline"],"phase":"phase_2","status":"active","brandName":"Higher-dose inhaled corticosteroids","genericName":"Higher-dose inhaled corticosteroids","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Higher-dose inhaled corticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation. Used for Asthma (maintenance and control), Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}